Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Safety of Recombinant Activated Factor VII (rFVIIa) in Patients with Congenital Hemophilia with Inhibitors: Overall Dose Exposure and Intervals Following >240 Mcg/Kg Doses Across Trial, Registry and Diary Studies,

Amy D. Shapiro, MD, Ellis J. Neufeld, MD, PhD, Victor S. Blanchette, MD, FRCPC, Hervé Chambost, MD, PhD, Peter Salaj, MD, Robert Z. Gut, MD, PhD, David L. Cooper, MD, MBA

Blood (2011) 118 (21): 3316.

https://doi.org/10.1182/blood.V118.21.3316.3316

Published: 2011

Journal Articles

Revisiting Splenectomy in Childhood Chronic Immune Thrombocytopenia At the Era of New Therapies: The French Experience

Nathalie Aladjidi, MD, Raoul Santiago, MD, Pondarré Corinne, MD, Anne Lambilliote, MD, Guy Leverger, MD, PhD, Claire Godard Sebillotte, MD, Helder Fernandes, PdD, Hervé Chambost, MD, PhD, Pierre Rohrlich, MD, PhD, Marlène Pasquet, MD, Thierry Leblanc, MD, Yves Perel, MD, PhD

Blood (2011) 118 (21): 2227.

https://doi.org/10.1182/blood.V118.21.2227.2227

Published: 2011

Journal Articles

Rituximab in 42 Cases of French Childhood Auto-Immune Haemolytic Anaemia: High Efficiency but Caution Required

Stéphane Ducassou, Nathalie Aladjidi, MD, Corinne Pondarre, Thierry Leblanc, MD, Hervé Chambost, MD, PhD, Armari-Alla Corinne, Pasquet Marlene, Helder Fernandes, PdD, Bayart Sophie, Piguet Christophe, Fouyssac Fanny, Monpoux Fabrice, Odile Lejars, Jeziorski Eric, Corinne Guitton, Guy Leverger, MD, PhD, Yves Perel, MD, PhD

Blood (2011) 118 (21): 2100.

https://doi.org/10.1182/blood.V118.21.2100.2100

Published: 2011

Journal Articles

Prevalence and Epitope Specificity of Non-Neutralizing Antibodies in Haemophilia A Patients without Inhibitors Using a Multiplex x-MAP Technology.

Aurélien Lebreton, Priscilla Lapalud, Hervé Chambost, Christine Biron-Andréani, Elodie Boissier, Catherine Pouymayou, Alain Marquès-Verdier, Claude Granier, Jean-Francois Schved, Géraldine Lavigne-Lissalde

Blood (2009) 114 (22): 3493.

https://doi.org/10.1182/blood.V114.22.3493.3493

Published: 2009

Journal Articles

FVIII Specific Memory B Lymphocytes in Hemophilia A with Inhibitors Treated by Immune Tolerance Induction.

Isabelle Diaz, Karine Bollore, Chantal Rothschild, Hervé Chambost, Ségolène Claeyssens, Edouard Tuaillon, Priscilla Lapalud, Jean-François Schved, Jean-Pierre Vendrell, Géraldine Lavigne-Lissalde

Blood (2009) 114 (22): 3162.

https://doi.org/10.1182/blood.V114.22.3162.3162

Published: 2009

Journal Articles

A 3′ RACE-PCR Method of Identification of Unknown MLL Gene Partner and Break-Point at RNA Level.

Christine Formisano-Tréziny, Fabienne Hermitte, Benoît Quilichini, Hervé Chambost, Gérard Michel, Jean Gabert

Blood (2006) 108 (11): 4275.

https://doi.org/10.1182/blood.V108.11.4275.4275

Published: 2006

Journal Articles

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A

Jenny Goudemand, Chantal Rothschild, Virginie Demiguel, Christine Vinciguerrat, Thierry Lambert, Hervé Chambost, Annie Borel-Derlon, Ségolène Claeyssens, Yves Laurian, Thierry Calvez, the members of the FVIII-LFB and Recombinant FVIII study groups

Blood (2006) 107 (1): 46–51.

https://doi.org/10.1182/blood-2005-04-1371

Published: 2006

Journal Articles

Intermediate Dose Methotrexate in Low-Risk Acute Lymphoblastic Leukemia. Results of the FRALLE 93A Protocol.

Yves Perel, Hervé Chambost, Virginie Gandemer, Thierry Leblanc, Schneider Pascale, Schmitt Claudine, Mariane Debré, Christiane Vermylen, Gérard Couillault, Jean-Paul Lamagnere, Marie-Françoise Auclerd, Guy Leverger, André Baruchel, the FRALLE group

Blood (2004) 104 (11): 1949.

https://doi.org/10.1182/blood.V104.11.1949.1949

Published: 2004

Journal Articles

Expression of gene MAGE-A4 in Reed-Sternberg cells

Hervé Chambost, Nicolas Van Baren, Francis Brasseur, Danièle Godelaine, Luc Xerri, Sylvaine Just Landi, Ivan Theate, Joel Plumas, Guilio C. Spagnoli, Gerard Michel, Pierre G. Coulie, Daniel Olive

Blood (2000) 95 (11): 3530–3533.

https://doi.org/10.1182/blood.V95.11.3530

Published: 2000

NARROW

Safety of Recombinant Activated Factor VII (rFVIIa) in Patients with Congenital Hemophilia with Inhibitors: Overall Dose Exposure and Intervals Following >240 Mcg/Kg Doses Across Trial, Registry and Diary Studies,

Revisiting Splenectomy in Childhood Chronic Immune Thrombocytopenia At the Era of New Therapies: The French Experience

Rituximab in 42 Cases of French Childhood Auto-Immune Haemolytic Anaemia: High Efficiency but Caution Required

Prevalence and Epitope Specificity of Non-Neutralizing Antibodies in Haemophilia A Patients without Inhibitors Using a Multiplex x-MAP Technology.

FVIII Specific Memory B Lymphocytes in Hemophilia A with Inhibitors Treated by Immune Tolerance Induction.

A 3′ RACE-PCR Method of Identification of Unknown MLL Gene Partner and Break-Point at RNA Level.

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A

Intermediate Dose Methotrexate in Low-Risk Acute Lymphoblastic Leukemia. Results of the FRALLE 93A Protocol.

Expression of gene MAGE-A4 in Reed-Sternberg cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only